Interleukin-7 enhances recruitment of MDSCs by regulating MCP-1 via JAK1/STAT3 signaling pathway in non-small cell lung cancer

Interleukin-7 enhances recruitment of MDSCs by regulating MCP-1 via JAK1/STAT3 signaling pathway in non-small cell lung cancer

Abstract Lung cancer is one of the most commonly diagnosed cancers worldwide and the leading cause of cancer-related deaths worldwide. In recent years, an increasing number of studies have shown that the tumor immune microenvironment (TIME) has a significant impact on the development of lung cancer....

Full description

Saved in:
Bibliographic Details
Main Authors: Huan Cheng, Yajiao Shao, Ao Zhang, Caixia Li, Xinxin Li, Yuxin Fu, Jian Ming
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
IL-7
MDSCs
MCP-1
NSCLC
Online Access:https://doi.org/10.1038/s41598-025-01868-5
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Lung cancer is one of the most commonly diagnosed cancers worldwide and the leading cause of cancer-related deaths worldwide. In recent years, an increasing number of studies have shown that the tumor immune microenvironment (TIME) has a significant impact on the development of lung cancer. Interleukin-7 (IL-7) is an essential cytokine for the adaptive immune system and plays an important immunoregulatory role in different types of tumors. However, the relationship between IL-7 and TIME in non-small cell lung cancer (NSCLC) is not yet known. This study found that the expression of MCP-1 and CD11b was correlated with the expression of IL-7/IL-7R. MCP-1, IL-7R, tumor differentiation and tumor stage were the strongest predictors of survival. In addition, IL-7 upregulates MCP-1 through JAK1/STAT3 pathway to affect the migration of MDSCs and exert tumor immunosuppressive effect. Furthermore, CCR2 inhibitor and depletion of MDSCs suppressed the promoting effect of IL-7 mediated development of lung cancer. These findings provided the important mechanism that IL-7 upregulate MCP-1 through JAK1/STAT3 pathway to recruit MDSCs and put forth blockage of CCR2 inhibitor and MDSCs recruitment as a prospective immunotherapy strategy for the treatment of NSCLC.
ISSN:2045-2322

Similar Items